COMBINATION OF AN ANTI-CANCER AGENT SUCH AS A TYROSINEKINASE INHIBITOR AND A STAT5 ANTAGONIST, PREFERABLY A THIAZOLIDINEDIONE, FOR ELIMINATING HEMATOLOGIC CANCER STEM CELLS IN VIVO AND FOR PREVENTING HEMATOLOGIC CANCER RELAPSE

摘要

Provided are methods for eliminating hematologic cancer stem cells in vivo, and thus preventing cancer relapse. The methods comprise a Signal Transducer and Activator of Transcription 5 (STAT5) antagonist (e.g., a PPARy agonist) after the patient has had ana initial course of treatment with an anti-cancer agent (e.g., a TKI), to eliminate residual cancer stem cells which cause re lapse.

主权项

1. A method of eliminating hematologic cancer stem cells in vivo comprising:
(A) administering to a patient with hematologic cancer, an effective amount of an anti-cancer agent; and (B) administering to the patient an effective amount of a Signal Transducer and Activator of Transcription 5 (STAT5) antagonist.